Organization Profile

You just read:

OncoGenex Announces Target Number of Events Reached in Phase 3 SYNERGY Trial of Custirsen in Metastatic Castrate-Resistant Prostate Cancer

News provided by

OncoGenex Pharmaceuticals, Inc.

Feb 11, 2014, 06:01 ET